Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.